Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00143689
Status:
COMPLETED
Last Update Posted:
2014-09-26
First Post:
2005-08-31
Brief Title:
NRTI-Sparing Pilot Study
Sponsor:
University of British Columbia
Organization:
University of British Columbia
Study Overview
Official Title:
A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve HIV-infected Patients
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare a nucleoside reverse transcriptase inhibitor-sparing NRTI-sparing regimen Kaletra nevirapine to two nucleoside reverse transcriptase inhibitor-based regimens Combivir nevirapine and Combivir Kaletra
Participants will be randomly assigned to receive one of the following drug combinations
lopinavirritonavir Kaletra and nevirapine Viramune twice a day
Combivir Zidovudine AZT plus lamivudine 3TC and nevirapine twice a day
Combivir and lopinavirritonavir twice a day
Participants will be randomly assigned to receive one of the following drug combinations
lopinavirritonavir Kaletra and nevirapine Viramune twice a day
Combivir Zidovudine AZT plus lamivudine 3TC and nevirapine twice a day
Combivir and lopinavirritonavir twice a day
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CTN 177 | None | None | None |